MARKET

TRVN

TRVN

Trevena
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.230
+0.010
+0.82%
Closed 17:34 09/24 EDT
OPEN
1.200
PREV CLOSE
1.220
HIGH
1.260
LOW
1.200
VOLUME
606.54K
TURNOVER
--
52 WEEK HIGH
3.400
52 WEEK LOW
1.091
MARKET CAP
202.35M
P/E (TTM)
-4.4149
1D
5D
1M
3M
1Y
5Y
Next Generation Disinfection Solutions Spread Beyond Healthcare
/PRNewswire/ -- Technology has played a major role in helping medical facilities, organizations and governments fight the pandemic. As a result, government funds were used to provide hospital with further necessary technology. Recently, even though the fea...
PR Newswire - PRF · 3d ago
Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit
CHESTERBROOK, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced th...
GlobeNewswire · 09/17 11:00
8 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to ...
Benzinga · 09/16 17:25
BRIEF-Imvax Appoints John M. Limongelli As Chief Legal Officer
reuters.com · 09/16 12:08
Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
CHESTERBROOK, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced th...
GlobeNewswire · 09/09 11:00
Powerful Software Plays a key Role in Keeping the Pandemic at Bay
/PRNewswire/ -- The pandemic has helped to increase awareness of the importance of maintaining hygiene to avoid transmission of pathogens in healthcare facilities and among the general populous. According to data provided by , the global personal protectiv...
PR Newswire - PRF · 09/08 13:00
BRIEF-Trevena Says On Sept. 3, Submitted IND Application For Trv045 To U.S. FDA
reuters.com · 09/07 20:49
BRIEF-Trevena Announces Two Olinvyk® Abstracts Highlighting Safety Data Accepted At Anesthesiology® 2021
reuters.com · 08/30 11:36
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TRVN. Analyze the recent business situations of Trevena through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TRVN stock price target is 5.33 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 107
Institutional Holdings: 36.22M
% Owned: 22.02%
Shares Outstanding: 164.51M
TypeInstitutionsShares
Increased
21
13.54M
New
27
1.99M
Decreased
15
4.94M
Sold Out
25
2.91M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Leon Moulder
President/Chief Executive Officer/Director
Carrie Bourdow
Chief Financial Officer/Senior Vice President
Barry Shin
Senior Vice President
Mark Demitrack
Senior Vice President
Robert Yoder
Independent Director
Scott Braunstein
Independent Director
Michael Dougherty
Independent Director
Marvin Johnson
Independent Director
Jake Nunn
Independent Director
Anne Phillips
Independent Director
Barbara Yanni
No Data
About TRVN
Trevena Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients affected by central nervous system (CNS) disorders. It is developing OLINVYK, a G-protein biased MOR ligand for acute pain in adults. It is developing TRV027, an angiotensin II type 1 (AT1), receptor selective agonist, for the treatment of acute lung injury contributing to acute respiratory distress syndrome (ARDS), and abnormal blood clotting in patients with COVID-19. It is developing TRV250, a G-protein biased delta-opioid receptor (DOR), is developed for the treatment of acute migraine.

Webull offers kinds of Trevena Inc stock information, including NASDAQ:TRVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TRVN stock methods without spending real money on the virtual paper trading platform.